Axsome Therapeutics, Inc. (AXSM) Insider Ownership

Data spanning the past 90 days through February 07, 2026 reveals that Axsome Therapeutics's three principal insider shareholders consist of Director Mark Coleman (452.07K shares), Director Roger Jeffs (57.51K shares), Chief Financial Officer Nick Pizzie (42.73K shares).

• The shareholding composition of Axsome Therapeutics (AXSM) reflects broad market participation, with institutional funds owning 74.72%, executive insider stakes representing 1.13%, with public and others accounting for 24.15%.
• Current insider holdings at Axsome Therapeutics account for 1.13% of total shares outstanding as of February 07, 2026, totaling roughly 569.24K shares from the company's 50.24Mn share base.
• Over the past 90 days ending February 07, 2026, insider ownership at Axsome Therapeutics decreased by 9.57%, with aggregate insider holdings declining from 629.46K to 569.24K shares.
• As of February 07, 2026, Chief Executive Officer Herriot Tabuteau recorded the highest insider purchase activity at Axsome Therapeutics, accumulating 251.80K shares during the past 90 days.
• In the 90-day period through February 07, 2026, Chief Executive Officer Herriot Tabuteau led insider selling transactions at Axsome Therapeutics, divesting 251.80K shares from their holdings.